The reason may be that EZH2 inhibitors also dynamically affect the tumor microenvironment, such as reprogramming the metabolic profile and/or weakening antitumor functions, such as producing an immunosuppressive effect by enhancing PD‐L1 expression.[15, 16, 39] Therefore, this study indicates that combination with immune therapy can compensate for the immunosuppressive effect of EZH2 inhibitors and exert synergistic antitumor effects. Here, EZH2 is linked to neoplasm.